Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015

Date: July 31, 2015
Pages: 68
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O23EFA6A9C2EN
Leaflet:

Download PDF Leaflet

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015’, provides an overview of the Onychomycosis (Tinea Unguium)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) Overview
Therapeutics Development
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview
Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies
Onychomycosis (Tinea Unguium) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Onychomycosis (Tinea Unguium) - Products under Development by Companies
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Anacor Pharmaceuticals, Inc.
Eisai Co., Ltd.
Helix BioMedix, Inc.
Hexima Limited
Meiji Seika Pharma Co., Ltd.
Moberg Pharma AB
NAL Pharmaceuticals Ltd.
Nihon Nohyaku Co., Ltd.
Novabiotics Limited
Nuvo Research Inc.
Viamet Pharmaceuticals, Inc.
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AN-2718 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-1224 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELS-160 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HB-1275 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HXP-124 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
luliconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ME-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAL-3216 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-213 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onychomycosis (Tinea Unguium) - Recent Pipeline Updates
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)
Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology
Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis
Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis
Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014
Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015
May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015
Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis
Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2015
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Limited, H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Limited, H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H2 2015
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H2 2015
Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2015
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd.1), H2 2015
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd.2), H2 2015
Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2015
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Anacor Pharmaceuticals, Inc.
Eisai Co., Ltd.
Helix BioMedix, Inc.
Hexima Limited
Meiji Seika Pharma Co., Ltd.
Moberg Pharma AB
NAL Pharmaceuticals Ltd.
Nihon Nohyaku Co., Ltd.
Novabiotics Limited
Nuvo Research Inc.
Viamet Pharmaceuticals, Inc.
Skip to top


Tinea Pedis - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 28 pages
Tinea Corporis - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 24 pages
Tinea Corporis – Pipeline Review, H1 2012 US$ 500.00 May, 2012 · 20 pages
Myasthenia Gravis - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 51 pages

Ask Your Question

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: